KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 41 days ( 0 % )
Last Price $20.00 0 %
High/ Low $20.00 - $20.00 0%
Chg 7 Days N/A $20.00 $20.00
Chg 30 Days N/A $20.00 $20.00
Chg 12 mos 200.75 % $6.65 $20.00
Trend - 3 mos N/A Width: 0 %
Trend - 12 mos 162.96 % Width: 85.85 %
Pred. range - 3 mos N/A - N/A -100.00 % - -100.00 %
Pred. range - 12 mos $37.20 - $69.13 85.99 % - 245.66 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Feb 24, 2020 - 37 days
Short/Long MA avg 3 mos Sell Feb 24, 2020 - 37 days
Short MA avg 12 mos Sell Jan 21, 2020 - 60 days
Long MA avg 12 mos Buy Nov 25, 2019 - 97 days
Short/Long MA avg 12 mos Buy Dec 04, 2019 - 91 days
Pivot Short Sell Apr 14, 2020 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About ArQule

ArQule ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesotheli... ARQL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT